Advertisement

Longitudinal Trends in Glycated Hemoglobin During and after Tuberculosis Treatment

Published:January 07, 2023DOI:https://doi.org/10.1016/j.diabres.2023.110242

      Abstract

      Aims

      To investigate the impact of pulmonary TB on glycemic status during and after TB treatment, and associations of glycemic trends with antidiabetic therapy and TB outcomes.

      Methods

      Data from two prospective cohort studies of adults in Chennai, India, with pulmonary TB were combined for this analysis. Participants were classified by baseline hemoglobin A1c (A1C) as having normoglycemia (NG; n = 74), prediabetes (pre-DM; n = 110), or diabetes (DM; n = 244). Repeat A1C measurements were performed at TB treatment months 3 and 6, and then 6 and 12 months after TB treatment completion.

      Results

      Median A1C at baseline declined after TB treatment initiation in all groups. No baseline NG or pre-DM participants progressed to DM by end of study, while 16.7% of baseline DM participants shifted to pre-DM or NG levels of A1C. In the baseline DM group, rising A1C after the intensive phase of TB treatment was significantly associated with adverse TB outcomes.

      Conclusions

      Incident TB promotes transient glucose elevation but was not conclusively shown to promote chronic dysglycemia. Rising A1C during and after TB treatment may predict unfavorable treatment response in persons presenting with A1C ≥ 6.5% at the time of TB diagnosis.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Diabetes Research and Clinical Practice
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Martinez L.
        • Zhu L.
        • Castellanos M.E.
        • et al.
        Glycemic control and the prevalence of tuberculosis infection: a population-based observational study.
        Clin Infect Dis. 2017; 65: 2060-2068
        • Magee M.J.
        • Khakharia A.
        • Gandhi N.R.
        • et al.
        Increased risk of incident diabetes among individuals with latent tuberculosis infection.
        Diabetes Care. 2022; 45: 880-887
        • Jeon C.Y.
        • Murray M.B.
        Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies.
        PLoS Med. 2008; 5: e152
        • Foe-Essomba J.R.
        • Kenmoe S.
        • Tchatchouang S.
        • et al.
        Diabetes mellitus and tuberculosis, a systematic review and meta-analysis with sensitivity analysis for studies comparable for confounders.
        PloS One. 2021; 16: e0261246
        • Huangfu P.
        • Ugarte-Gil C.
        • Golub J.
        • Pearson F.
        • Critchley J.
        The effects of diabetes on tuberculosis treatment outcomes: an updated systematic review and meta-analysis.
        Int J Tuberc Lung Dis. 2019; 23: 783-796
        • Gautam S.
        • Shrestha N.
        • Mahato S.
        • et al.
        Diabetes among tuberculosis patients and its impact on tuberculosis treatment in South Asia: a systematic review and meta-analysis.
        Sci Rep. 2021; 11: 2113
        • Magee M.J.
        • Bloss E.
        • Shin S.S.
        • et al.
        Clinical characteristics, drug resistance, and treatment outcomes among tuberculosis patients with diabetes in Peru.
        Int J Infect Dis. 2013; 17: e404-e412
        • Lee P.H.
        • Fu H.
        • Lai T.C.
        • et al.
        Glycemic control and the risk of tuberculosis: a cohort study.
        PLoS Med. 2016; 13: e1002072
        • Martinez N.
        • Kornfeld H.
        Diabetes and immunity to tuberculosis.
        Eur J Immunol. 2014; 44: 617-626
        • Kornfeld H.
        • West K.
        • Kane K.
        • et al.
        High prevalence and heterogeneity of diabetes in patients with TB in South India: a report from the Effects of Diabetes on Tuberculosis Severity (EDOTS) study.
        Chest. 2016; 149: 1501-1508
        • Boillat-Blanco N.
        • Ramaiya K.L.
        • Mganga M.
        • et al.
        Transient hyperglycemia in patients with tuberculosis in Tanzania: implications for diabetes screening algorithms.
        J Infect Dis. 2016; 213: 1163-1172
        • Gupte A.N.
        • Mave V.
        • Meshram S.
        • et al.
        Trends in HbA1c levels and implications for diabetes screening in tuberculosis cases undergoing treatment in India.
        Int J Tuberc Lung Dis. 2018; 22: 800-806
        • Martinez N.
        • Cheng C.Y.
        • Ketheesan N.
        • et al.
        mTORC2/Akt activation in adipocytes is required for adipose tissue inflammation in tuberculosis.
        EBioMedicine. 2019; 45: 314-327
        • Hotamisligil G.S.
        Inflammation, metaflammation and immunometabolic disorders.
        Nature. 2017; 542: 177-185
        • Jais A.
        • Einwallner E.
        • Sharif O.
        • et al.
        Heme oxygenase-1 drives metaflammation and insulin resistance in mouse and man.
        Cell. 2014; 158: 25-40
        • Andrade B.B.
        • Pavan K.N.
        • Sridhar R.
        • et al.
        Heightened plasma levels of heme oxygenase-1 and tissue inhibitor of metalloproteinase-4 as well as elevated peripheral neutrophil counts are associated with tuberculosis-diabetes comorbidity.
        Chest. 2014; 145: 1244-1254
        • Prada-Medina C.A.
        • Fukutani K.F.
        • Pavan K.N.
        • et al.
        Systems immunology of diabetes-tuberculosis comorbidity reveals signatures of disease complications.
        Sci Rep. 2017; 7: 1999
        • Kumar N.P.
        • Fukutani K.F.
        • Shruthi B.S.
        • et al.
        Persistent inflammation during anti-tuberculosis treatment with diabetes comorbidity.
        eLife. 2019; 8: e46477
        • Kumar N.P.
        • Moideen K.
        • Viswanathan V.
        • et al.
        Elevated levels of matrix metalloproteinases reflect severity and extent of disease in tuberculosis-diabetes co-morbidity and are predominantly reversed following standard anti-tuberculosis or metformin treatment.
        BMC Infect Dis. 2018; 18: 345
        • Kumar N.P.
        • Moideen K.
        • Viswanathan V.
        • et al.
        Heightened circulating levels of antimicrobial peptides in tuberculosis-diabetes co-morbidity and reversal upon treatment.
        PloS One. 2017; 12: e0184753
        • Draznin B.
        • Aroda V.R.
        • Bakris G.
        • et al.
        Classification and diagnosis of diabetes: standards of medical care in diabetes - 2022.
        Diabetes Care. 2022; 45: S17-S38
        • Ralph A.P.
        • Ardian M.
        • Wiguna A.
        • et al.
        A simple, valid, numerical score for grading chest x-ray severity in adult smear-positive pulmonary tuberculosis.
        Thorax. 2010; 65: 863-869
      1. Indian Council of Medical Research. ICMR Guidelines for Managment of Type 2 Diabetes. New Delhi, 2018. https://main.icmr.nic.in/sites/default/files/guidelines/ICMR_GuidelinesType2diabetes2018_0.pdf

      2. World Health Organization. Global Tuberculosis Report 2021. Geneva, 2021 https://www.who.int/publications/i/item/9789240037021

        • Li M.
        • Chen T.
        • Hua Z.
        • et al.
        Global, regional, and national prevalence of diabetes mellitus in patients with pulmonary tuberculosis: a systematic review and meta-analysis.
        Diabetol Metab Syndr. 2021; 13: 127
        • Critchley J.A.
        • Restrepo B.I.
        • Ronacher K.
        • et al.
        Defining a research agenda to address the converging epidemics of tuberculosis and diabetes: part 1: epidemiology and clinical management.
        Chest. 2017; 152: 165-173
        • Tabarsi P.
        • Baghaei P.
        • Marjani M.
        • et al.
        Changes in glycosylated haemoglobin and treatment outcomes in patients with tuberculosis in Iran: a cohort study.
        J Diabetes Metab Disord. 2014; 13: 123
        • Marik P.E.
        • Bellomo R.
        Stress hyperglycemia: an essential survival response!.
        Crit Care. 2013; 17(2):305
        • Ali Abdelhamid Y.
        • Kar P.
        • Finnis M.E.
        • et al.
        Stress hyperglycaemia in critically ill patients and the subsequent risk of diabetes: a systematic review and meta-analysis.
        Crit Care. 2016; 20: 301
        • Anjana R.M.
        • Shanthi Rani C.S.
        • Deepa M.
        • et al.
        Incidence of diabetes and prediabetes and predictors of progression among Asian Indians: 10-year follow-up of the Chennai Urban Rural Epidemiology Study (CURES).
        Diabetes Care. 2015; 38: 1441-1448
        • Eckel R.H.
        • Kahn S.E.
        • Ferrannini E.
        • et al.
        Obesity and type 2 diabetes: what can be unified and what needs to be individualized?.
        J Clin Endocrinol Metab. 2011; 96: 1654-1663
        • Niazi A.K.
        • Kalra S.
        Diabetes and tuberculosis: a review of the role of optimal glycemic control.
        J Diabetes Metab Disord. 2012; 11: 28
        • Riza A.L.
        • Pearson F.
        • Ugarte-Gil C.
        • et al.
        Clinical management of concurrent diabetes and tuberculosis and the implications for patient services.
        Lancet Diabetes Endocrinol. 2014; 2: 740-753
        • Shewade H.D.
        • Jeyashree K.
        • Mahajan P.
        • et al.
        Effect of glycemic control and type of diabetes treatment on unsuccessful TB treatment outcomes among people with TB-Diabetes: A systematic review.
        PloS One. 2017; 12: e0186697
        • Liu Q.
        • You N.
        • Pan H.
        • et al.
        Glycemic trajectories and treatment outcomes of patients with newly diagnosed tuberculosis: a prospective study in Eastern China.
        Am J Respir Crit Care Med. 2021; 204: 347-356
        • Mi F.
        • Tan S.
        • Liang L.
        • et al.
        Diabetes mellitus and tuberculosis: pattern of tuberculosis, two-month smear conversion and treatment outcomes in Guangzhou.
        China. Trop Med Int Health. 2013; 18: 1379-1385
        • Singhal A.
        • Jie L.
        • Kumar P.
        • et al.
        Metformin as adjunct antituberculosis therapy.
        Sci Transl Med. 2014; 6(263):263ra159
        • Nandakumar K.V.
        • Duraisamy K.
        • Balakrishnan S.
        • et al.
        Outcome of tuberculosis treatment in patients with diabetes mellitus treated in the revised national tuberculosis control programme in Malappuram District, Kerala, India.
        PloS One. 2013; 8: e76275
        • Shriraam V.
        • Mahadevan S.
        • Anitharani M.
        • et al.
        Reported hypoglycemia in type 2 diabetes mellitus patients: prevalence and practices-a hospital-based study.
        Indian J Endocrinol Metab. 2017; 21: 148-153
        • Kubjane M.
        • Berkowitz N.
        • Goliath R.
        • et al.
        Tuberculosis, human immunodeficiency virus, and the association with transient hyperglycemia in periurban South Africa.
        Clin Infect Dis. 2020; 71: 1080-1088
        • Ho-Pham L.T.
        • Nguyen U.D.T.
        • Tran T.X.
        • Nguyen T.B.
        Discordance in the diagnosis of diabetes: comparison between HbA1c and fasting plasma glucose.
        PLoS One. 2017; 12: e0182192